Health canada authorizes moderna's covid-19 vaccine in young children (6 months-5 years)

Two-dose series takes one month to complete, with similar vaccine efficacy estimates against omicron to those seen in adults cambridge, ma / accesswire / july 14, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that health canada has approved the use of moderna's mrna covid-19 vaccine, spikevax™, in a two-dose series of 25 Μg per dose for active immunization to prevent covid-19 caused by sars-cov-2 in children aged 6 months to 5 years. until now, children under 5 were the only age group not yet eligible in canada for vaccination against covid-19.
MRNA Ratings Summary
MRNA Quant Ranking